NeuroTrauma Sciences
Manufacturing · Georgia, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2655 Northwinds Pkwy Ste 5C, Alpharetta,...Phone Number
(833) 278-2888Website
www.neurotraumasciences.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About NeuroTrauma Sciences
NeuroTrauma Sciences (NTS) is a clinical stage biopharmaceutical company established in 2016, dedicated to enhancing the treatment of stroke patients, specifically focusing on acute ischemic stroke and chronic stroke. The company is currently advancing its lead compound, NTS-104, through Phase 1 clinical trials, expected to complete in 2025. NTS is led by a team of experienced professionals in neuroscience and drug development, aiming to innovate in the field of neuroprotection. Their target clients include healthcare providers and patients affected by stroke, as well as potential partners in the pharmaceutical industry.Explore more
NeuroTrauma Sciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NeuroTrauma Sciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if NeuroTrauma Sciences had a recent Job posting/layoffs
Product Launch: Get notified when NeuroTrauma Sciences launches new products
Earning: See what the market has to say on NeuroTrauma Sciences recently announced quarterly report
Check if NeuroTrauma Sciences has recently received funding, and reach out quickly before it becomes old news!
Check out if NeuroTrauma Sciences is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once NeuroTrauma Sciences has new funding data
Congratulate Masked Content for being promoted to Masked Content at NeuroTrauma Sciences
NeuroTrauma Sciences, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to NeuroTrauma Sciences
Compare insights from companies similar to NeuroTrauma Sciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NeuroTrauma Sciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NeuroTrauma Sciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NeuroTrauma Sciences.
NeuroTrauma Sciences Tech Stack
A closer look at the technologies used by NeuroTrauma Sciences
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
New Hire
Executive Move
New Hire
Executive Move
NeuroTrauma Sciences News & Media
NeuroTrauma Sciences Appoints Kevin Pong, PhD, MBA as Chief Business Officer
Accomplished Business Development and Licensing Executive to Drive NTS's Business Development and Partnering Activities ATLANTA, July 31, 2023 /PRNewswire/ -- NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company developing neuroprotective therapeutics for treating central...NeuroTrauma Sciences Commences First-in-Human Dosing in the US of Investigational Neuroprotective Drug NTS-104
Phase 1 safety study of NTS-104 is initiated in healthy volunteers Compound is being developed for stroke and other Central Nervous System (CNS) injuries ATLANTA, June 1, 2023 /PRNewswire/ -- NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company developing neuroprotective...NeuroTrauma Sciences Announces Key Appointments to its Executive Leadership Team
Marc de Somer, MD, ScD, MPH, MSc, MBA, appointed Chief Medical Officer Martin Rabe, MSc, appointed Executive Vice President of Regulatory Affairs and Quality Assurance ATLANTA, May 10, 2023 /PRNewswire/ -- NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company developing...NeuroTrauma Sciences Neuroactive Compound NTS-105 Decreases Cell Death in Preclinical Model of Traumatic Brain Injury
Poster presentation at 39th Annual Symposium of the National Neurotrauma Society ATLANTA, June 27, 2022 /PRNewswire/ -- NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company developing a portfolio of disease-modifying therapeutic candidates to treat the devastating effects...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NeuroTrauma Sciences
Sign Up For FreeTo access detailed company insights
NeuroTrauma Sciences (NTS) is a clinical stage biopharmaceutical company established in 2016, dedicated to enhancing the treatment of stroke patients, specifically focusing on acute ischemic stroke and chronic stroke. The company is currently advancing its lead compound, NTS-104, through Phase 1 clinical trials, expected to complete in 2025. NTS is... Read More
